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Letters to the editor
Friedreich's ataxia and intrathecal
chemotherapy in a patient with
lymphoblastic lymphoma
Friedreich's ataxia (FA) is the most common spino-cerebellar
degeneration of unknown etiology, with signs and symptoms
developing from 18 months to 24 years of age. Common neuro-
logical signs are limb and truncal ataxia, dysarthria, areflexia of
the lower extremities; pyramidal signs, loss of position and
vibratory sense evolve gradually. Distal amyotrophy, horizontal
nystagmus and optic atrophy are less common. Non-neuro-
logical features include kyphoscoliosis, pes cavus and cardio-
myopathy. Pathological features of FA are narrowed spinal
cord with cell loss and gliosis in the spinocerebellar and
corticospinal tracts and in the posterior column, Clarke's
column and depleted dorsal root ganglia, such as cranial nerve
nuclei VIII, X and XII. Large myelinated peripheral nerves are
lost, and myocardial fibers degenerated.
We treated a 16-year-old male affected by FA, who suffers
from a stage IIA bulky lymphoblastic T-cell non-Hodgkin's
lymphoma with mediastinal presentation. FA-related signs
were kyphoscoliosis, hypertrophical cardiomyopathy and cer-
ebellar mild ataxia. A cerebral magnetic resonance showed a
moderate spino-bulbar atrophy.
At the time of diagnosis, because of rapidly worsening
dyspnea, mediastinal radiotherapy was performed in another
hospital and, after partial recovery, the patient was admitted to
our Department to start systemic chemotherapy.
Although lumbar puncture did not find malignant cells, we
performed a prophylactic intrathecal administration with
Methotrexate 10 mg, ara-C 70 mg and hydrocortisone 30 mg.
Concomitant systemic chemotherapy with a five-drug regimen
(adriamycin 25 mg/m2 dd 1-8, vincristine 1 mg dd 1-8, cyclo-
phosphamide 600 mg dd 1-8, prednisone 50 mg dd l -> 8 and
methotrexate 1.5 g/m2 d 15) was also started. Six cycles of
intrathecal and systemic chemotherapy were administered.
No acute side effects appeared during or after the intrathecal
treatments, nor any neurological complications after over two
years' follow-up; neurological manifestations related to FA are
unchanged and the patient is still in complete remission.
We think it is very important to report this single experience,
considering that no data are available about the feasibility and
toxicity of intrathecal chemotherapy in patients affected by
central nervous system degenerations, probably because of the
extreme rarity of this combined health problem.
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Cisplatin-refractory,
HER2/neu-expressing germ-cell
cancer: Induction of remission by the
monoclonal antibody Trastiizumab
Patients with cisplatin-refractory germ-cell cancer or relapse
following cisplatin-based first-line therapy exhibit a very poor
prognosis. Only 15%—20% of patients are long-term survivors
after standard- or high-dose salvage chemotherapy [1].
The HER2/neu receptor has been shown to be expressed in
a variety of tumors, including breast, prostate and ovarian
cancer. A recently published report indicates that about 30%
of all refractory germ-cell cancers may overexpress HER2/neu
[2]. Trastuzumab (Herceptin®), a mouse/human IgGl chimeric
antibody not only binds to the HER2/neu receptor and sub-
sequently inhibits cell proliferation, but is also able to mediate
an antibody-dependent, cell-mediated cytotoxicity in vitro [3].
To date, trastuzumab has shown a marked clinical activity in
patients with HER2/neu positive breast cancer.
We report a 51-year-old male with heavily pretreated, cispla-
tin-refractory and HER2/neu overexpressing germ-cell cancer
in whom a partial remission was achieved with Trastumab
therapy.
The patient had undergone a right-sided inguinal orchiec-
tomy, as well as a retroperitoneal lymph node dissection for
embryonal carcinoma in 1982. In April 1993 he was found to
have paraaortal lymph node metastases. During the following
six years, the patient suffered four additional relapses, all
located in the retroperitoneum and in the lungs. Treatment
consisted of various chemotherapy regimens, including four
cisplatin-based regimens. In addition, retroperitoneal and lung
metastases were repeatedly resected.
In May 1998, the patient was referred to our department for
further therapy. Staging procedures revealed lung metastases
and a retroperitoneal mass, as well as an elevated AFP-level.
The patient received several additional salvage chemotherapy
regimens, including paclitaxel and gemcitabine, both of which
are known to be potentially active in metastatic GCT [1].
However, remission could not be induced and the AFP-
level rose constantly. At this time, the lung metastases specimen,
resected in 1998 was examined for HER2/neu expression.
Immunohistochemical staining (ABC-test; Novocasta Inc.)
showed a significant HER2/neu overexpression with 90%—100%
of all tumor cells being HER2/neu positive (Figure 1).
After obtaining informed consent, the patient was started
on experimental treatment with trastuzumab. A loading dose
of 4 mg/kg body weight was administered in week 1, followed
by 2 mg/kg body weight once weekly. AFP-level at the start of
trastuzumab was 6000 K.U/1. The AFP-level began to decline
after the first administration of trastuzumab and declined to
700 KU/1 after seven weeks of therapy.
Trastuzumab therapy was very well tolerated with no side
effects. Repeat echocardiograms showed no signs of cardiac
toxicity. Overall, the patient received eight weeks of therapy.
Unfortunately, the AFP-level started to rise following two
weeks rest and the patients was started on an alternative
palliative chemotherapy regimen.
Despite the high cure rate achievable in testicular cancer
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